Clinical trial
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an…
NCT00092417 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092417 |
|---|---|
| Title | Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009) |
| Official title | Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | Comparator: Varicella Zoster Virus Vaccine |
| Enrollment | 695 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Sep 27, 2004 |
| Last update posted | Oct 7, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: